Here, we highlight the significance of mitochondria! DAMPs and discuss their contribution to inflammation and development of human pathologies.”
“Schizophrenia see more is thought to arise in part from abnormal gray matter (GM), which are partly shared by the relatives

of the probands. DISC1 is one of the most promising susceptibility genes of schizophrenia and a SNP rs821597 (A) in the gene was associated with schizophrenia in Han Chinese population. In this study, 61 healthy controls and 72 with schizophrenic patients were genotyped at rs821597, and underwent T1-weighted MRI for the density of GM. The results showed that the risk allele (A) carriers had higher GM density in regional left parahippocampal gyrus and right orbitofrontal cortex in schizophrenic patients, but had reduced GM density of these brain regions in healthy controls. The DISC1 variant rs821597 may confer risk for schizophrenia by its effects on the regional GM in left parahippocampal gyrus and right orbitofrontal cortex

with other risk factors for schizophrenia. (c) 2012 Elsevier Ireland Ltd. All rights reserved.”
“Purpose: Comorbidity assessment is essential to triage of care for men with prostate cancer. We identified long-term risks of other cause mortality associated with comorbidities in the Charlson index and applied these to the creation of a prostate cancer specific comorbidity index.

Materials and Methods: We sampled DNA Damage inhibitor 1,598 cases of prostate cancer diagnosed in 1997 to 2004 at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers. We used Cox proportional hazards modeling to Org 27569 determine the risks of other cause mortality associated with comorbidities and used these hazard ratios to re-weight the Charlson index. We then compared the ability of each index to predict other cause mortality.

Results: Cox modeling showed that moderate to severe liver disease, metastatic solid tumor, lymphoma and leukemia carried the highest risk (HR greater than 5) for other cause mortality, followed by moderate to severe chronic obstructive pulmonary disease, moderate to severe renal disease, dementia, hemiplegia and

congestive heart failure (HR 2.5 to less than 3.5). The revised and original Charlson indices performed similarly in predicting other cause mortality across all patients (c-index 0.816 vs 0.802). However, in survival analysis our revised index identified 137 men with a greater than 90% probability of other cause mortality within 10 years while the original Charlson identified only 51. In multivariate modeling the odds of 5-year other cause mortality for men with original Charlson scores 1, 2, 3 and 4+ were 2.9, 6.0, 9.2 and 29.8, respectively, compared with 3.9, 6.2, 12.8 and 84.2 for the revised index.

Conclusions: Re-weighting the Charlson index allowed for more accurate identification of men at highest risk for other cause mortality.